Meeting
2022 ASCO Annual Meeting
A phase 1/2 study of BLU-945 in patients with common activating EGFR-mutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress.
Authors
Elaine Shum
Perlmutter Cancer Center, New York University Langone Health, New York, NY
Elaine Shum , Yasir Y Elamin , Zofia Piotrowska , David R Spigel , Karen L. Reckamp , Julia K Rotow , Daniel Shao-Weng Tan , Sun Min Lim , Tae Min Kim , Chia-Chi Lin , Terufumi Kato , Jagan Parepally , Faris Albayya , Melinda Louie-Gao , Tessa Weinig , Alena Zalutskaya , Koichi Goto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04862780
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9156)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9156
Abstract #
TPS9156
Poster Bd #
132b
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).
First Author: Keunchil Park
Poster
2022 ASCO Annual Meeting
Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
First Author: Conor Ernst Steuer
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2021 ASCO Annual Meeting
Phase II two-arm study of tepotinib plus osimertinib in patients with EGFR-mutant NSCLC and acquired resistance to first-line osimertinib due to MET amplification: INSIGHT 2.
First Author: Viola Weijia Zhu